Additive mixture effects of estrogenic chemicals in human cell-based assays can be influenced by inclusion of chemicals with differing effect profiles by Evans, RM et al.
Additive Mixture Effects of Estrogenic Chemicals in
Human Cell-Based Assays Can Be Influenced by Inclusion
of Chemicals with Differing Effect Profiles
Richard Mark Evans*, Martin Scholze, Andreas Kortenkamp
Institute for the Environment, Brunel University, Uxbridge, Middlesex, United Kingdom
Abstract
A growing body of experimental evidence indicates that the in vitro effects of mixtures of estrogenic chemicals can be well
predicted from the estrogenicity of their components by the concentration addition (CA) concept. However, some studies
have observed small deviations from CA. Factors affecting the presence or observation of deviations could include: the type
of chemical tested; number of mixture components; mixture design; and assay choice. We designed mixture experiments
that address these factors, using mixtures with high numbers of components, chemicals from diverse chemical groups,
assays with different in vitro endpoints and different mixture designs and ratios. Firstly, the effects of mixtures composed of
up to 17 estrogenic chemicals were examined using estrogenicity assays with reporter-gene (ERLUX) and cell proliferation
(ESCREEN) endpoints. Two mixture designs were used: 1) a ‘balanced’ design with components present in proportion to
a common effect concentration (e.g. an EC10) and 2) a ‘non-balanced’ design with components in proportion to potential
human tissue concentrations. Secondly, the individual and simultaneous ability of 16 potential modulator chemicals (each
with minimal estrogenicity) to influence the assay outcome produced by a reference mixture of estrogenic chemicals was
examined. Test chemicals included plasticizers, phthalates, metals, PCBs, phytoestrogens, PAHs, heterocyclic amines,
antioxidants, UV filters, musks, PBDEs and parabens. In all the scenarios tested, the CA concept provided a good prediction
of mixture effects. Modulation studies revealed that chemicals possessing minimal estrogenicity themselves could reduce
(negatively modulate) the effect of a mixture of estrogenic chemicals. Whether the type of modulation we observed occurs
in practice most likely depends on the chemical concentrations involved, and better information is required on likely human
tissue concentrations of estrogens and of potential modulators. Successful prediction of the effects of diverse chemical
combinations might be more likely if chemical profiling included consideration of effect modulation.
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Introduction
Humans are typically exposed to multiple chemicals with
diverse effects [1]. Despite this, experimental studies usually
examine binary or ternary combinations. We recently reviewed
173 experimental mixture studies and found that the majority had
tested binary combinations and that fewer than one in four studies
had examined mixtures with seven or more components [2].
Of the available mathematical concepts for the prediction of
mixture effects, concentration addition (CA) has proven the most
useful and has been shown to have good predictive power, see
reviews by [1,3]. Ermler et al. recently showed that mixtures of 17
anti-androgenic chemicals with varied structural features produced
effects in vitro that were predictable by CA [4]. However, a study of
a similar number of estrogenic chemicals observed small deviations
from the predictions made using CA [5]. Silva et al. studied five
mixtures with from3 to 16 components in theESCREENassay.The
effects of twomixtures were accurately predicted byCA, whilst three
showed slight overestimation by CA. It was hypothesised that the
deviationwas due to increasedmetabolismof steroidal estrogens and
it was suggested that CYP1B1 activation and reduction in steroidal
estrogen concentrations could ‘‘contribute to the shortfall from
[CA]’’ [5]. This hypothesis was tested by predicting the mixture
effect if the steroidal estrogens had been removed bymetabolism (i.e.
they make no contribution to the overall effect) and comparing this
scenario with the observed result. Few other studies have examined
mixtures with a similar number of components, and factors that
remain to be addressed include the assay used, the number and type
of chemical studied and the mixture design. Further studies in this
area are required in order to resolve whether predictability by CA
should be the default expectation for multicomponent mixtures of
estrogens. If so, CA could be routinely applied for the assessment of
such mixtures.
In this paper we aimed to address the impact of choice of assay
system, the number and nature of included chemicals, the mixture
design, and the possibility of effect modulation. Our approach to
each of these issues is now described in turn.
Assay System
To evaluate the possible contribution of the model system, we
have compared the predictability of mixture effects in two in vitro
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assays with differing endpoints, the ERLUX and ESCREEN
assays. These assays utilize a luminescent reporter gene and a cell
proliferation endpoint respectively. The ESCREEN assay has
been widely used in the study of environmental estrogens [6,7] and
the ERLUX is one of a number of available reporter gene assays
that are becoming increasingly used in the field [8]. Both assays
are established in vitro assays based on human cell lines, however
we had an expectation that the more apical endpoint used in the
ESCREEN would provide greater potential for deviations of
mixture effects from those predicted compared to the more
constrained ERLUX endpoint, which is a luminescent signal
indicating activation of an engineered reporter-gene.
Number of Components
We have chosen to study mixtures with a high number of
components (up to 30 components for a mixture of estrogens with
potential modulators). We aimed for a high number of
components because systematic testing of all possible mixture
combinations, for example recursively studying binary, ternary,
quaternary etc combinations, is not practical and we considered
that the most interesting combinations, from a toxicological
scenario, are those of higher numbers of components.
Type of Chemical
We wished to avoid testing mixtures of only congeneric
chemicals, since this does not reflect likely exposure scenarios
and is likely to limit the possible effect ‘repertoires’ that can be
observed. Chemicals were selected from chemical groups to which
human exposure is likely, especially through food, and included:
plasticizers including phthalates, metals, polychlorinated biphenyls
(PCBs), phytoestrogens, polyaromatic hydrocarbons (PAHs), het-
erocyclic amines, antioxidants, UV filters, musks, polybrominated
diphenylethers (PBDEs) and parabens.
Mixture Design
We have also studied mixtures designed from two different
perspectives. Firstly, we have used a design in which all
components were combined in proportion to their potency. This
was achieved by choosing a mixture ratio in proportion to selected
effect concentrations, for example an EC10 or EC25; we refer to
this approach as a ‘‘balanced’’ design since each component is
expected to contribute equally to the overall effect of the mixture.
The advantage of this design is that the contribution of any one
component is equally likely to be evident (as a contribution
towards an additive mixture effect or as a deviation from
additivity) as any other component, and so the number of possible
interactions that could be evident is maximized. The balanced
design also eliminates the possibility of performing a mixture
experiment in which the combined effect is due almost entirely to
the actions of a few or only one component. Secondly, we have
used mixtures based on the ratio of the possible human tissue
concentration. Accurate, consistent data on human tissue levels is
not generally available, but the literature contains some in-
formation that can be employed with caution. We refer to this
approach as a ‘‘non-balanced’’ design, since the design is not based
on the potency of each component, and the mixture effect may be
dominated by one or several of the mixture components, if that is
the observed human exposure situation. The purpose of this design
is to allow the testing of mixtures with a composition that is
arguably more realistic that the equieffective design, since it is
unlikely that humans are exposed to chemicals in a fixed
proportion to their potency on any one given endpoint. It is
possible to criticise this design because it is based on often
incomplete human exposure data, with extrapolation between
reported and compared tissue levels, reports derived from different
publications, analytical systems and geographical populations.
However, even if the underlying ratio is subsequently found to be
inappropriate, the test design still represents a different mixture
ratio to that of the balanced design and so in any case constitutes
a further test of the CA concept. Because of these caveats, we do
not intend to draw strong conclusions about the actual human
situation from these experimental observations, but rather propose
that they contribute to future experimental designs and serve to
test the wider suitability of CA for use in modeling mixture effects.
Effect Modulation
We recognised the need to study chemicals that were more
varied than congeners (see above) and also extended this further to
examine the effects of including chemicals that had weak or no
estrogenicity themselves, which we termed possible effect mod-
ulators. Possible modulators included those that had been reported
as estrogenic in the literature but that did not exhibit such
behaviour in our experimental systems. An example of this is the
carcinogen PhIP, which has been reported to be an estrogen [9]
but did not behave as such in our hands [10].
A practical issue in studying effect modulators is that to compare
around 15 modulators with around 15 actives, and mixtures
thereof, is not practically possible. For example, to test 15
modulators against 15 actives in triplicate, would require 675
experimental runs, and would not even provide any data on
possible modulation by combinations of chemicals. Therefore, we
employed an approach of screening the individual modulators
with low power, and simultaneously testing an equimolar mixture
of all modulators. The use of an equimolar design is suitable when
the actual effect is not known, e.g. we do not know how, or indeed
if, modulation will occur. The data from low power screening and
from mixture testing is then evaluated collectively and the mixture
result is assessed for its ability to cross-validate the screening
results. With this approach we propose that meaningful observa-
tions were made using a much more feasible 20 plates and that the
approach could be used or extended for similar situations.
Materials and Methods
Ethics Statement
The two human cell lines used in this work were obtained
commercially or as a gift, and their origins were previously
described in publications from other groups: the ESCREEN assay
uses cloned MCF-7 cells (described in [6]) that were gifted to us;
the ERLUX assay uses T47D-KBluc cells (described in [11]) that
were purchased commercially.
Chemicals
Cell culture reagents were purchased from Invitrogen (Paisley,
UK). Test compounds were obtained as listed in Table 1.
Estrogenicity Assay, Reporter Gene Endpoint (ERLUX)
T47D-KBluc cells were obtained from the ATCC and the
protocol established by the depositing authors was followed [8].
Cells were routinely grown in RPMI media (with 10% foetal calf
serum (FCS)). For seven days prior to experiments, cells were
maintained in low estrogen conditions by the use of pre-assay
media (RPMI, 10% charcoal-dextran stripped FCS, no antibio-
tics). For experiments, cells were seeded in white polystyrene 96
well plates at a density of 10,000 cells/well and allowed to attach
for 24 hours before removal of media, and application of test
chemicals. Test chemicals were dissolved in ethanol to give stock
solutions of millimolar concentrations. Test and control solutions
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were obtained by dilution of ethanolic stocks in dosing media
(phenol red-free RPMI, 5% charcoal-dextran stripped FCS, no
antibiotics), and in all cases the final concentration of ethanol was
0.5%. The positive control was 1 nM estradiol. Positive and
vehicle controls were run as eight replicate wells per plate, and
compounds were tested in a dilution series comprising eight
concentrations, each concentration tested in triplicate. As
recommended by Wilson et al. two additional controls were also
included on each plate: 1) vehicle control plus an antiestrogen, ICI
182,780 (1 mM), and 2) positive control plus ICI 182,780 (1 mM).
These additional controls were used to monitor the background
level of estrogenicity, and full experiments were excluded if vehicle
showed high levels of estrogenicity or if the positive could not be
suppressed by the antiestrogen (data not shown). A crude measure
of toxicity was provided by comparing values for treatments that
were not positive, with the value of the vehicle control. Toxicity
would be expected to decrease these small (but non-zero) values
towards zero, and this was not observed for any of the tested
chemicals (data not shown). 24 hours after application of test and
control solutions, a volume of Steady-Glo assay reagent (Promega)
equal to the volume of culture media was added and plates were
incubated for ten minutes, with shaking, to allow for cell lysis.
Plates were then loaded into a plate reader (FLUOstar Optima,
BMG Labtech) and incubated for a further ten minutes in the
dark, followed by measurement of luminescence. To reduce
variation, the temperature of the plate reader chamber was
maintained at 27uC throughout.
Estrogenicity Assay, Mitogenic Endpoint (ESCREEN)
The ESCREEN assay was performed using cloned MCF-7 cells
(described in [6], gifted from A. Soto, Boston) and the established
ESCREEN method [6] was followed using an adapted 96-well
format [11]. Cells were cultured in DMEM (5% FCS). For
experiments, cells were seeded in clear polystyrene 96 well plates
at a density of 2,500 cells/well and allowed to attach for 24 hours
before washing with rinse media (phenol red-free DMEM, no
Table 1. Details of test chemicals.
Chemical name Abbreviation Supplier (Catalogue number) CAS number
2,29,3,4,49,5,59-heptachloro biphenyl (PCB #180) PCB180 UltraScientific (RPC-094) 35065-29-3
2,29,4,49,5,59-hexachloro biphenyl (PCB #153) PCB153 UltraScientific (RPC-047) 35065-27-1
2,49-dichlorobiphenyl (PCB #8) PCB008 UltraScientific (RPC-089) 34883-43-7
2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine PhIP Apollo (OR1700T), MP Biomedicals (154190),
Toronto Research Chemicals (A617000)
105650-23-5
2-Amino-3,8-dimethyl imidazo [4,5-f] quinoxaline MeIQx Apollo (ORO660T) 77500-04-0
3,39,4,49,5-pentachlorobiphenyl (PCB #126) PCB126 LGC (ERM AC821) 57465-28-8
4-methylbenzylidene camphor 4MBC Merck (1.05383.0100) 36861-47-9
Benzo [a] pyrene BaP Sigma SUPELCO (48564) 50-32-8
Benzophenone-3 BP3 Sigma Aldrich (H36206) 131-57-7
Bisphenol A BPA Sigma (239658) 80-05-7
Brominated diphenyl ether-100 BDE100 LGC (CIL-EO-4194) 189084-64-8
Butyl benzyl phthalate BBP Sigma (36927) 85-68-7
Butylated hydroxyl anisole BHA Sigma (W218308) 25013-16-5
Butylated hydroxytoluene BHT Sigma (W218405) 128-37-0
Butylparaben BUTYLP Sigma (H9503) 94-26-8
Cadmium chloride CdCl2 Sigma (C3141) 7790-78-5
Coumestrol COU Sigma Fluka (27883) 479-13-0
Di butyl phthalate DBP Sigma (36736) 84-74-2
Di ethyl hexyl phthalate DEHP Sigma (36735) 117-81-7
Di ethyl phthalate DEP Sigma (36737) 84-66-2
Enterolactone ENL Sigma Fluka (45199) 78473-71-9
Estradiol E2 Sigma (E2758) 50-28-2
Ethinyl estradiol EE2 Sigma (E4876) 57-63-6
Fluoranthene FLUOR Sigma Riedel-de-Haen (45504) 206-44-0
Galaxolide (HHCB) GAL LGC (DEOMUS-01) 1222-05-5
Genistein GEN Lancaster (L14171) 446-72-0
Lead nitrate Pb (NO3)2) Sigma (203580) 10099-74-8
Mercury chloride HGCl2 Sigma (429724) 7487-94-7
Methylparaben METHYLP Acros Organics (126961000) 99-76-3
Naringenin NAR Sigma Fluka (71155) 67604-48-2
Propylparaben PROPYLP Sigma (P53357) 94-13-3
Tonalide (AHTN) TON LGC (DE-MUS-02) 21145-77-7
doi:10.1371/journal.pone.0043606.t001
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supplements). Estrogen deprivation (by use of charcoal-dextran
stripped serum and removal of phenol red) was not used prior to
seeding because this results in an almost complete lack of
attachment of cells. Test chemicals were dissolved in ethanol to
give stock solutions of millimolar concentrations. Test and control
solutions were diluted prior to application in dosing media (phenol
red free DMEM, 10% charcoal-dextran stripped FCS). The final
concentration of ethanol was 0.5% in test and control wells. The
positive control was 25 nM estradiol and the final concentration of
ethanol in all wells was 0.5%. The raw value of vehicle controls
was monitored for any indication of increasing background
estrogenicity, raw values were typically 0.06–0.08 optical density
units (ODU) and experiments were rejected if the vehicle value
(averaged per plate) exceeded 0.1 ODU. At all stages, media
removal from cells was carried out gently and in a controlled
fashion by use of an electronic multichannel pipette set to the
lowest speed possible. Controls were run as eight replicate wells
per plate and compounds were tested in a dilution series
comprising eight concentrations, each concentration tested in
two replicate wells per plate. The plate layout was designed to
reduce variation due to evaporation and spreading of test
chemicals, and had been previously optimised in the laboratory
[11]. After application of test solutions, plates were incubated for
120 hours before fixation with 10% trichloroacetic acid and
sulforhodamine B (SRB) staining to measure protein and allow the
indirect quantification of cell number.
Modulation studies (ESCREEN only). Modulation studies
comprised screening of individual modulators in low power
experiments accompanied by parallel testing of an equimolar
mixture of all modulators. This combination of low power
screening and mixture testing provides the opportunity to assess
a high number of chemicals (16 in this case) without a prohibitive
amount of experimental effort. In this case the effects of 16
modulators could be evaluated using a total of 19 experimental
plates (16 for screening and 3 for mixture testing).
To screen individual potential modulators, the concentration of
a mixture of estrogenic chemicals (13 components, equieffective
design) that evoked an approximately 50% response was selected
as the baseline and each modulator was tested over a range of
concentrations for their ability to increase (positive modulation) or
decrease (negative modulation) the observed ESCREEN response.
To normalize for small changes in the absolute value of the
positive control and the control response to the selected REFmix
concentration, the response evoked by the REFmix control on each
plate was defined as the 50% effect and all modulator study results
are normalized to that value.
A mixture of modulators (MODmix) was also tested and was
composed with a fixed ratio of equimolar concentrations, since the
activity of each modulator was not known at the time of designing
the mixture.
Concentration-response Analysis
Raw results from either in vitro assay were normalised by
subtraction of the mean value of on-plate vehicle controls and then
division by the mean value of on-plate positive controls.
Experiments were performed on different days meaning that
Table 2. Estrogenicity of individual compounds (ERLUX).
Concentration Response Function EC10 EC25
Substance (in order
of EC10) RM h‘1 h‘2 h‘3 hmin h‘max M [CI] M [CI]
EE2 G.logit I 125.57 11.01 0.27 0 1.05 6.51E-13 [4.19E-13 – 8.77E-13] 1.32E-12 [9.68E-13 – 1.55E-12]
Estradiol logit 34.98 3.07 – 0 1.23 6.53E-13 [4.29E-13 – 9.97E-13] 1.45E-12 [1.03E-12 – 2.02E-12]
Coumestrol logit 26.52 3.26 – 0 1.01 1.58E-9 [1.19E-9 – 2.26E-9] 3.42E-9 [2.50E-9 – 4.90E-9]
Genistein logit 38.76 5.23 – 0 1.48 1.24E-8 [1.15E-8 – 1.34E-8] 1.96E-8 [1.86E-8 – 2.06E-8]
Bisphenol A logit 29.24 4.68 – 0 1.44 1.55E-7 [1.39E-7 – 1.73E-7] 2.58E-7 [2.43E-7 – 2.75E-7]
Naringenin logit 30.45 5.04 – 0 1.14 3.10E-7 [2.57E-7 – 4.74E-7] 5.06E-7 [4.40E-7 – 6.15E-7]
Butylparaben logit 20.97 3.88 – 0 3.31 4.97E-7 [2.72E-7 – 6.75E-7] 8.81E-7 [6.19E-7 – 1.05E-6]
Benzo [a] pyrene logit 15.94 2.97 – 0 0.90 8.62E-7 [6.64E-7 – 1.09E-6] 2.06E-6 [1.60E-6 – 2.59E-6]
Propylparaben logit 21.65 4.22 – 0 2.60 1.30E-6 [1.01E-6 – 1.60E-6] 2.21E-6 [1.86E-6 – 2.54E-6]
4MBC G.logit I 81.54 17.24 0.12 0 0.82 1.81E-6 [1.34E-6 – 2.86E-6] 5.00E-6 [4.08E-6 – 6.15E-6]
Benzophenone-3 (BP3) logit 15.69 3.28 – 0 1.77 2.27E-6 [1.46E-6 – 2.88E-6] 4.61E-6 [3.40E-6 – 5.67E-6]
Tonalide logit 7.74 1.53 – 0 0.28 3.61E-6 [1.74E-6 – 9.63E-6] 2.06E-4 [2.96E-5 – 5.25E-4]
Enterolactone logit 15.32 3.24 – 0 1.04 3.77E-6 [3.47E-6 – 4.10E-6] 8.18E-6 [7.49E-6 – 9.06E-6]
Galaxolide logit 18.54 3.82 – 0 0.91 3.93E-6 [3.05E-6 – 5.02E-6] 7.73E-6 [6.68E-6 – 8.77E-6]
BD100 logit 11.34 2.68 – 0 1.72 5.36E-6 [4.46E-6 – 6.65E-6] 1.28E-5 [9.71E-6 – 1.55E-5]
Methylparaben logit 12.76 3.09 – 0 2.06 8.14E-6 [5.49E-6 – 1.13E-5] 1.71E-5 [1.25E-5 – 2.29E-5]
Fluoranthene logit 16.72 3.85 – 0 0.16 6.00E-5 [3.70E-5 – 1.22E-4] –
Mixtures with ratio as defined in Table 4.
Mixture 1 logit 13.91 3.24 – 0 1.24 8.94E-6 [7.37E-6 - 1.15E-5] 1.90E-5 [1.75E-5 - 2.25E-5]
Mixture 2 probit 12.18 2.21 – 0 1.97 5.69E-7 [4.91E-7 - 6.67E-7] 9.54E-7 [8.35E-7 - 1.12E-6]
EC10, EC25: concentration producing 10% and 25% effect, respectively. Values in brackets denote the upper and lower limits of the approximate 95% confidence interval;
the column ‘‘RM’’ indicates the mathematical regression function as defined by [13]; h‘1, h‘2, h‘3, h‘max estimated model parameters, given for concentrations expressed
in M (rounded values); hmin were not estimated, but set to 0 relating to the mean value of the negative vehicle controls.
doi:10.1371/journal.pone.0043606.t002
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results for different dilution series and different batches of the test
chemicals were obtained on different days. Each single chemical
was tested in three or more independent experiments. Use of
normalisation meant that data from different experiments could be
reliably combined and compared, as discussed previously [12].
Data was expressed relative to the positive control, rather than as
fold change from the vehicle response, for two reasons. Firstly, to
anchor the response data to a meaningful response, namely the
maximal response of the cognate ligand (estradiol), and secondly,
to avoid spurious changes on the response axis due to the very low
background estrogenicity which was achieved in vehicle controls in
both assay systems. When the vehicle response is numerically
small, chance variations that are not experimentally significant can
nonetheless significantly affect the apparent fold change of positive
test chemicals.
Data from multiple replicate experiments were pooled and
statistical concentration response regression analyses were con-
ducted for each single compound according to the best-fit
approach [13]. Effect concentrations (ECx) were defined relative
to the effects of the estradiol concentration used as the positive
control, for example EC50 is the concentration producing an effect
of 50% of the positive control (estradiol, 1 nM (ERLUX) or
25 nM (ESCREEN)).
Prediction of Mixture Effects
Results from regression analysis for each test chemicals were
used to predict the CA effect for fixed-ratio mixtures designed on
1) equi-effective concentrations (balanced design), 2) possible
human serum levels (non-balanced design). The original mathe-
matical formulation of CA that defines for a mixture composed of
n components with concentration c1 of the first component, c2 of
the second component, and cn for the n-th component a combi-
nation effect X is
c1
ECX1
z
c2
ECX2
z::: cn
ECXn
~1 ð1Þ
Here, ECX1, ECX1 …, ECXn are the concentrations of the
individual components that on their own produce the same effect
X as the mixture [14,15] The quotients cn/ECXn are called toxic
units and scale all compounds in the mixture relative to their
toxicity. They can be interpreted as the contribution of the
compound to the total mixture concentration that is expected to
produce the mixture effect X. According to equation 1, a mixture
effect for a pre-defined effect level X is described only implicitly.
However, if the individual concentrations ci are expressed as
relative fractions pi to the total mixture concentration ECxMix, then
equation 1 can be re-arranged to
Table 3. Estrogenicity of individual compounds (ESCREEN).
Concentration Response Function EC10 EC25
Substance (by order
of EC10) RM h‘1 h‘2 h‘3 hmin h‘max M [CI] M [CI]
EE2 logit 26.38 2.36 – 0 1.14 6.35E-13 [5.63E-14 – 1.53E-12] 1.81E-12 [3.34E-13 – 3.39E-12]
Estradiol G.logit I 24.30 2.23 1.08 0 1.33 1.12E-12 [6.18E-13 – 1.40E-12] 3.12E-12 [2.46E-12 – 3.80E-12]
Coumestrol G.logit I 19.59 0.87 394769 0 1.31 1.56E-9 [9.45E-10 – 2.18E-9] 5.00E-9 [3.79E-9 – 6.37E-9]
Genistein logit 17.63 2.37 – 0 0.93 4.61E-9 [1.68E-9 – 1.34E-8] 1.36E-8 [6.45E-9 – 2.95E-8]
Bisphenol A G.logit I 19.06 2.69 2.251 0 1.21 4.52E-8 [3.41E-8 – 5.81E-8] 8.18E-8 [6.59E-8 – 1.04E-7]
Naringenin logit 16.78 2.96 – 0 1.10 3.60E-7 [2.53E-7 – 4.97E-7] 8.33E-7 [6.82E-7 – 1.09E-6]
Butylparaben logit 16.61 3.01 – 0 1.01 5.71E-7 [3.60E-7 – 8.35E-7] 1.32E-6 [9.84E-7 – 1.77E-6]
BDE100 G.logit I 90.69 18.09 0.095 0 0.71 7.04E-7 [5.37E-7 – 9.43E-7] 2.41E-6 [2.01E-6 – 2.77E-6]
4MBC logit 17.65 3.20 – 0 0.63 8.99E-7 [6.52E-7 – 1.12E-6] 2.21E-6 [1.49E-6 – 3.05E-6]
Propylparaben logit 17.05 3.22 – 0 1.09 9.97E-7 [8.84E-7 – 1.10E-6] 2.16E-6 [1.96E-6 – 2.34E-6]
Benzophenone-3 G.logit I 38.08 7.86 0.23 0 0.63 1.30E-6 [6.00E-7 – 2.30E-6] 4.31E-6 [3.05E-6 – 5.29E-6]
Tonalide logit 15.54 2.95 – 0 0.46 1.97E-6 [1.30E-6 – 2.83E-6] 6.13E-6 [4.70E-6 – 8.21E-6]
Enterodiol Weibull 20.70 4.08 – 0 0.45 3.85E-6 [1.32E-6 – 4.38E-6] 7.45E-6 [6.10E-6 – 8.02E-6]
Enterolactone Weibull 19.22 4.05 – 0 1.39 4.15E-6 [2.02E-6 – 5.00E-6] 7.22E-6 [5.50E-6 – 8.27E-6]
Galaxolide logit 16.10 3.39 – 0 0.69 5.39E-6 [3.98E-6 – 7.92E-6] 1.23E-5 [8.96E-6 – 1.82E-5]
Methylparaben Weibull 12.19 2.77 – 0 0.79 7.64E-6 [5.56E-6 – 9.97E-6] 1.80E-5 [1.42E-5 – 2.12E-5]
Fluoranthene logit 17.10 4.05 – 0 0.38 3.39E-5 [3.34E-5 – 4.19E-5] 8.85E-5 [8.45E-5 – 9.85E-5]
Mixtures with ratio as defined in Table 4.
Mixture 3a logit 16.39 3.45 – 0 0.99 4.07E-6 [3.40E-6 - 4.48E-6] 8.49E-6 [7.98E-6 - 9.03E-6]
Mixture 3b logit 20.15 4.22 – 0 1.03 5.00E-6 [3.67E-6 - 6.12E-6] 9.07E-6 [7.54E-6 - 1.08E-5]
Mixture 3c logit 18.16 3.83 – 0 0.93 5.00E-6 [3.67E-6 - 6.13E-6] 9.79E-6 [8.64E-6 - 1.09E-5]
Mixture 3d logit 15.44 3.15 – 0 0.80 3.07E-6 [2.63E-6 - 3.41E-6] 7.15E-6 [6.01E-6 - 9.04E-6]
Mixture 4 logit 11.44 2.11 – 0 1.51 2.12E-7 [1.56E-7 - 2.81E-7] 6.52E-7 [5.33E-7 - 8.02E-7]
EC10, EC25: concentration provoking 10% and 25% effect, respectively. Values in brackets denote the upper and lower limits of the approximate 95% confidence interval;
the column ‘‘RM’’ indicates the mathematical regression function as defined by [13]; h‘1, h‘2, h‘3, h‘max estimated model parameters, given for concentrations expressed
in M (rounded values); hmin were not estimated, but set to 0 relating to the mean value of the negative vehicle controls.
doi:10.1371/journal.pone.0043606.t003
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Table 5. Statistical uncertainty of predicted and observed effect concentrations for mixtures (ERLUX).
Effect level x Effect concentration ECxmix [M]
Observed Predicted by CA Predicted by IA
Mean 95% CI Mean 95% CI Mean 95% CI
Mixture 1:17 components (ratio as defined in Table 4)
10% 8.94E-6 [7.37E-6 – 1.15E-5] 7.47E-6 [6.61E-6 – 8.55E-6] 1.35E-5 [8.98E-6 – 1.68E-5]
25% 1.90E-5 [1.75E-5 – 2.25E-5] 1.62E-5 – 1.79E-5* 3.17E-5 [2.54E-5 – 3.57E-5]
50% 3.82E-5 [3.22E-5 – 4.64E-5] 2.71E-5 – 3.24E-5* 6.37E-5 [5.50E-5 – 6.94E-5]
Mixture 2:14 components (ratio as defined in Table 4)
10% 5.69E-7 [4.91E-7 – 6.67E-7] 3.22E-7 [2.69E-7 – 3.91E-7] 5.41E-7 [4.05E-7 – 7.20E-7]
25% 9.54E-7 [8.35E-7 – 1.12E-6] 6.44E-7 – 6.44E-7* 1.10E-6 [8.91E-7 – 1.43E-6]
50% 1.57E-6 [1.35E-6 – 1.91E-6] 1.98–7 – 1.23E-6* 2.06E-6 [1.72E-6 – 2.53E-6]
CA, Concentration Addition; IA, Independent Action; CI, Confidence Interval. All predictions statistically significant to the observed ECs are shown in bold. *Effect
mixture concentration for effect levels higher than the lowest estimated compound maximal model asymptote are extrapolated either (i) by assuming no contribution
of this compound to the overall mixture effect (toxic unit equals zero), or (ii) by setting the compounds’ toxic unit to a fixed level equalling the value at the mixture
concentration producing an effect of 0.7*hmax (see Table 2). The right side of the interval corresponds to (i) and the left side to (ii), defining the range of possible CA
predictions.
doi:10.1371/journal.pone.0043606.t005
Table 6. Statistical uncertainty of predicted and observed effect concentrations for mixtures (ESCREEN).
Effect level x Effect concentration ECxmix [M]
Observed Predicted by CA Predicted by IA
Mean 95% CI Mean 95% CI Mean 95% CI
Mixture 3a: 16 components (ratio as defined in Table 4)
10% 4.07E-6 [3.40E-6 – 4.48E-6] 3.71E-6 [2.76E-6 – 4.24E-6] 6.00E-6 [2.80E-6 – 8.21E-6]
25% 8.49E-6 [7.98E-6 – 9.03E-6] 9.36E-6 [8.09E-6 – 1.02E-5] 1.41E-5 [8.98E-6 – 1.82E-5]
50% 1.77E-5 [1.57E-5 – 2.11E-5] 1.75E-05 – 3.24E-5* 2.94E-5 [2.26E-5 – 3.51E-5]
Mixture 3b: 15 components (ratio as defined in Table 4)
10% 5.00E-6 [3.67E-6 – 6.12E-6] 3.78E-6 [2.98E-6 – 4.32E-6] 6.18E-6 [3.25E-6 – 8.79E-6]
25% 9.07E-6 [7.54E-6 – 1.08E-5] 9.51E-6 [8.31E-6 – 1.03E-5] 1.44E-5 [9.82E-6 – 1.84E-5]
50% 1.64E-5 [1.36E-5 – 2.25E-5] 2.40E-5 – 3.30E-5* 2.99E-5 [2.38E-5 – 3.63E-5]
Mixture 3c:14 components (ratio as defined in Table 4)
10% 5.00E-6 [3.67E-6 – 6.13E-6] 4.00E-6 [3.18E-6 – 4.63E-6] 6.68E-6 [3.47E-6 – 9.22E-6]
25% 9.79E-6 [8.64E-6 – 1.09E-5] 1.00E-5 [8.76E-6 – 1.09E-5] 1.54E-5 [1.07E-5 – 1.94E-5]
50% 1.96E-5 [1.67E-5 – 2.52E-5] 2.46E-5 – 3.51E-5* 3.15E-5 [2.52E-5 – 3.81E-5]
Mixture 3d:14 components (ratio as defined in Table 4)
10% 3.07E-06 [2.63E-6 – 3.41E-6] 2.46E-6 [1.36E-6 – 2.93E-6] 3.17E-6 [1.14E-6 – 4.75E-6]
25% 7.15E-06 [6.01E-6 – 9.04E-6] 6.50E-6 [4.87E-6 – 7.24E-6] 8.22E-6 [4.35E-6 – 1.10E-5]
50% 1.85E-05 [1.40E-5 – 3.08E-5] 1.61E-5 – 2.65E-5* 1.84E-5 [1.28E-5 – 2.29E-5]
Mixture 4:13 components (ratio as defined in Table 4)
10% 2.12E-7 [1.56E-7 – 2.81E-7] 2.80E-7 [1.94E-7 – 3.60E-7] 3.30E-7 [1.70E-7 – 5.55E-7]
25% 6.52E-7 [5.33E-7 – 8.02E-7] 7.78E-7 [6.19E-7 – 9.02E-7] 8.42E-7 [5.46E-7 – 1.22E-6]
50% 1.77E-6 [1.47E-6 – 2.24E-6] 2.11E-6 – 2.51E-6* 1.98E-6 [1.52E-6 – 2.56E-6]
CA – Concentration Addition, IA – Independent Action, CI – Confidence Interval; All predictions statistically significant to the observed ECs are shown in bold; *Effect
mixture concentration for effect levels higher than the lowest estimated compound maximal model asymptote are extrapolated either (i) by assuming no contribution
of this compound to the overall mixture effect (toxic unit equals zero), or (ii) by setting the compounds’ toxic unit to a fixed level equalling the value at the mixture
concentration producing an effect of 0.7*hmax (see Table 3). The right side of the interval corresponds to (i) and the left side to (ii), defining the range of possible CA
predictions.
doi:10.1371/journal.pone.0043606.t006
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which allows the direct calculation of the mixture concentration
that is expected to produce the mixture effect X. To form
a prediction curve, equation 2 is iterated through for various effect
levels resulting in sets of effects and their associated predicted
mixture concentration which are then plotted to produce a graph
of the effect prediction.
Both equations 1 and 2 require knowledge of the concentration
of each mixture component that on its own produces the effect
magnitude under consideration. For this reason, these equations
cannot be used for predicting mixture effects that exceed the
maximal effect of the least efficacious component, because those
effect concentrations cannot be defined. We have referred to these
chemicals as ‘sub-maximal’ because they have an effect maxima
that is lower than that of the positive control, estradiol. This
situation is not uncommon for estrogenic compounds where dose-
response curves with different maxima have been observed, for
example in the ESCREEN [11]. To overcome this limitation, we
developed a pragmatic solution that extrapolates the toxic units of
sub-maximal mixture components to effect levels beyond their
maximal efficacy. In short, the toxic unit of a sub-maximal
component is fixed above a certain concentration in the mixture
and used for all higher concentration in the mixture to calculate
the mixture concentration for higher effect levels. Here we
followed two approaches: by defining as cut-off value the
concentration that produces an effect equaling 70% of the
maximal model asymptote (hmax, see Tables 2 and 3), we used
either (i) the associated toxic unit in the mixture prediction as fixed
maximal contribution, or (ii) we set the toxic unit to zero (minimal
contribution). These two worst-case calculations define a range of
possible CA predictions, with the left side of the interval (higher
effects) corresponding to (i) and the right side (lower effects) to (ii).
The composition of each tested mixture is listed in Table 4. The
statistical uncertainty for mixture effects predictions was de-
termined using the bootstrap method [16] and expressed as 95%
confidence limits for the predicted mean estimate (Tables 5 and 6).
Differences between predicted and observed effect doses were
deemed statistically significant when the 95% confidence belts of
the prediction did not overlap with those of the experimentally
observed mixture effects.
The mathematical and statistical procedures used for calculating
mixture effects according to independent action (IA) are described
in [12]. Effects predicted by IA are included in the results tables for
completeness (Tables 5 and 6), but only CA predictions are
included in the figures for clarity and because the experimental
situation used CA was deemed the more appropriate model.
Results
Single Chemical Testing
Concentration response curves for the single components
included in mixtures of estrogens are shown for the ERLUX
(Figure 1, left; Table 2) and ESCREEN (Figure 1, right; Table 3)
assays. Figure 1 (left graph) shows that chemicals tested in the
ERLUX exhibited a wide range of potencies, for example EC10
values ranged from picomolar to high micromolar concentrations.
The most potent chemicals tested were estradiol and ethinylestra-
diol, and the least potent was fluoranthene. Supramaximal
responses (responses greater than the maximal response for the
cognate ligand estradiol) were quite commonly observed in the
ERLUX assay, for example for genistein (200% of estradiol
maxima), bisphenol A (150%), butylparaben (300%) and benzo-
phenone-3 (150%). Supramaximal effects were observed over the
range of concentrations tested, i.e. they did not appear to be
related to the potency of the chemical. The supramaximal effect
varied between chemicals and could be up to around 300% of the
maximal effect of estradiol, e.g. for butylparaben. Supramaximal
effects are a known feature of the ERLUX assay [8], and are also
observed in similar reporter-gene assays [17,18].
Figure 1 (right graph) shows that chemicals tested in the
ESCREEN exhibited a similarly wide range of potencies to the
ERLUX. However supramaximal effects were not typically
observed in the ESCREEN, instead a number of chemicals
showed submaximal responses, e.g. they exerted a maximal effect
that was substantially lower than that of estradiol, for example
4MBC and benzophenone-3 both showed clear maxima at effects
levels of 60–70% that of estradiol.
Comparison of assays. Figure 1 (middle graph) shows
a comparison of the 10% effect concentrations (EC10) determined
for chemicals tested in the ERLUX and ESCREEN assays.
Excellent correlation between the two assays was seen when
compared at EC10 (r
2 = 0.996).
Whilst most of the chemicals screened showed similar results in
the two assays, differences were observed for phthalates and for
benzo [a] pyrene. Four phthalates were tested in both assays:
DEHP, BBP, DBP and DEP. In ERLUX we found that DEHP
and DBP showed no estrogenicity whilst both BBP and DEP were
estrogenic (activity seen at concentrations of 0.1–1 mM and above)
(Figure 2). In the case of BBP there was evidence for toxicity within
the dose-response analysis, and this appeared to occur close to the
concentration at which estrogenicity was observed. In ESCREEN,
we found that all four phthalates showed activity. At the highest
concentrations shown in Figure 2, both DEHP and BBP showed
a decline in response, which may indicate toxicity. The
estrogenicity of DEHP occurred at concentrations greater than
1 mM, and toxicity was seen before a full estrogenic response was
reached (toxicity began at 5 mM). Because of these differences
between assays and, in some cases, the narrow margin between
effect and apparent toxicity, phthalates were not included in the
mixtures of estrogens, however they were examined as potential
modulatory components, see ‘‘Modulator studies’’ section below.
Benzo [a] pyrene (BaP) was tested alone in ERLUX prior to
being examined as an effect modulator, and was found to be active
(see Figure 1). This was unexpected, based on the literature, for
example [19], and meant that BaP was included in the mixtures of
estrogenic chemicals for testing in the ERLUX (see ‘‘Mixture
Studies’’ section next). Conversely, BaP was not active when tested
alone in the ESCREEN and therefore it was not included in any of
the mixtures of active estrogens tested in the ESCREEN, however
BaP was tested as an effect modifier in the ESCREEN (see
‘‘Modulator studies’’ section below).
Mixture Studies (‘‘Balanced’’ Design: Fixed Ratio Effective
Concentration)
In the ERLUX assay, we tested an equieffective mixture of 17
active components (Mixture 1 in Table 4; fixed ratio of EC10
levels) over an effect range from 0 to 100% effect. Testing revealed
good agreement with CA, as shown by the experimental data
overlapping the predicted CA line (Figure 3A). Figure 3A also
shows the use of extrapolation to extend the predictive rage of the
CA model (See ‘‘Methods’’ section). Without extrapolation, the
CA model equations limit the predicted effect to the lowest
maximal effect of any of the tested components, which can even be
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as low as 10–20% for some chemicals, see Figure 1 and Tables 2
and 3.
In the ESCREEN a 16 component mixture (Mixture 3a in
Table 4; fixed ratio of EC25 levels), differing from the mixture
tested in ERLUX only by the omission of BaP and the use of
EC25s rather than EC10s to set the fixed mixture ratio, showed
good agreement with the CA prediction (Figure 3B). As was done
in the ERLUX, extrapolation was also used to extend the CA
prediction for the ESCREEN data.
Three additional balanced mixtures were also tested in the
ESCREEN and were composed as listed in Table 4 (mixtures 3b,
3c, 3d). Mixtures 3b and 3c omit ethinylestradiol (3b) and estradiol
(3c) and were included to examine a potential small deviation from
additivity hypothesized to be due to the steroid nature of these two
chemicals which was previously observed [5]. In the event, no such
deviation was observed in our studies and these mixtures simply
constitute testing of differently composed mixtures whose effects
showed good conformance to CA (Table 6). Mixture 3d was
included in order to test a mixture containing the brominated
flame retardant (BDE100), which is a potentially important human
estrogen [20–22]. Mixture 3d also showed good conformance to
CA (Table 6).
Mixture Studies (‘‘Non-balanced’’ Design: Fixed Ratio in
Proportion to Human Exposure Levels)
In order to examine the robustness of the use of CA to predict
mixture effects we repeated mixture studies in both assays using
a second mixture design, which we have termed a ‘non- balanced’
design to contrast it with the balanced, equieffective design used so
far (Figure 3A, 3B). For example, in a 17 component, equieffective
mixture each component is expected to contribute one seventeenth
of the mixture effect. The balanced design gives the best chance of
seeing a deviation from a mixture effect since a change in the
contribution of any one single component is equally likely to be
detected, however this situation is not likely in realistic mixture
scenarios. The ‘non-balanced’ design uses a fixed ratio of
concentrations that was initially based on the approximate tissue
concentrations that have been reported to be found in human
tissues, mostly serum, and was then refined to prevent any single
component, such as estradiol, from dominating the mixture effect.
It is not our intention that this should be considered as
a comprehensive model for the human exposure scenario, since
the database for tissue concentrations is incomplete, dominated by
certain frequently measured compounds and is a massive simpli-
fication of the complexity of human exposure (ignoring at least
temporal and geographical variations in exposure).
The mixtures used similar components to the mixtures designed
with a fixed ratio of equieffective concentrations, but with some
omissions: ethinylestradiol was removed because it has different
exposure consideration to almost all of the other components due
to its use as a pharmaceutical; galaxolide and tonalide were not
included for technical reasons (a temporary lack of availability of
the pure compounds).
Figures 3C and 3D show the results of testing mixtures with
a ‘non- balanced’ design in the ERLUX (fourteen components,
Figure 3C, Mixture 2 (Table 4)) and in the ESCREEN (thirteen
components, Figure 3D, Mixture 4 (Table 4)). The distribution of
toxic units indicates how balanced a mixture design is, and these
distributions are shown in Figure 4 for the same four mixtures
shown in Figure 3. Figure 4C and D show clearly that the non-
balanced design results in a greater contribution from 6 of the
components, and that the contributions are heavily skewed. In
contrast, for mixtures with a balanced design the bars in the TU
distributions are of a similar length (Figure 4A, B). In both assays,
the effects of these less-balanced mixtures was well predicted by
CA. Toxic unit distributions (Figure 4C, 4D) showed that the
components contributing most to these mixture effects were
estradiol, coumestrol, naringenin, bisphenol A, genistein and
benzophenone-3. It is important to note that the relative
contribution assigned to this list of components is due to both
the levels reported to occur in human tissue and to the mixture
design. Consequently this approach could be used to prioritise
Figure 1. Concentration-response curves from single chemical testing and inter-assay correlation. Graphs show the results of testing
single estrogenic chemicals in the ERLUX (left) or ESCREEN (right) assays. Each single chemical was tested in three or more independent experiments.
Results are shown as the best fit regression model, for which details are provided Tables 2 and 3. Middle graph shows the correlation between EC10
values obtained in the ERLUX (y-axis) and ESCREEN (x-axis) assays.
doi:10.1371/journal.pone.0043606.g001
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components for regulatory attention and/or action only if reliable
human exposure levels were used as the input.
Modulation Studies
Modulation studies were carried out only using the ESCREEN
assay because we considered that a cell proliferation assay would
have more potential to show any modulation than a reporter-gene
assay in which the link between chemicals and their effects is
engineered and presumed to be more direct.
In these modulator studies, we examined 16 single chemicals
(listed in Table 7) and an equimolar mixture of all 16 components
for their ability to modulate the effects of a reference mixture
(REFmix) which contained 14 food additives and contaminants
(Table 1, Mixture 3d). The concentration of REFmix was chosen
to evoke a response of around 50–60% in the ESCREEN, which
gave the opportunity to detect any increase in effect (positive
modulation) as well as any decrease (negative modulation). Single
chemicals were tested individually in single experiments (screen-
ing) and then a mixture composed using a fixed ratio of equal
molarities was subjected to repeated testing.
Potential modulators were selected from a pool of previously
tested chemicals that were of interest due to their presence in food
and that had the potential for endocrine disruption based on the
literature. Potential modulators included both those found to have
estrogenicity at the higher end of the tested range (.1 mM, usually
10–100 mM; phthalates and PCB126) and those that were not
estrogenic when tested alone (heavy metals, antioxidants, hetero-
cyclic amines, PCBs, poly aromatic hydrocarbons).
Effect of a mixture of 16 potential modulators. The 16
potential modulators were combined to make a ‘mixture of
modulators’ (MODmix). The MODmix was designed using a fixed
ratio of equimolar concentrations, rather than a fixed ratio of equi-
effective levels because it was not known beforehand whether the
modulators would have a common effect (for example some may
have increased the REFmix effect whilst others may have reduced
it) and because the commonalities between the modulators are
expected to be fewer than, for example, a mixture of estrogenic
compounds which all have estrogenicity in common and which
effect can thus be used as the basis for equieffective designs.
Figure 2. Different effects of phthalates in ERLUX and ESCREEN. Graphs show the results of testing four phthalates (DEHP, BBP, DBP, DEP) in
the ERLUX (A–D) and ESCREEN (E–H) assays. Each phthalate was tested in two independent experiments in ERLUX (triplicate testing within assay) and
three (DEHP) or one (BBP, DBP, DEP) experiments in ESCREEN (duplicate testing within assay).
doi:10.1371/journal.pone.0043606.g002
Figure 3. Predicted and observed effects of mixtures. A) 17 component mixture at fixed mixture ratio proportional to the individual EC10’s
(ERLUX, Mixture1 (Table 4)). B) 16 component mixture at fixed mixture ratio proportional to the individual EC25’s (ESCREEN, Mixture3a (Table 4)). C) 14
component mixture at fixed ratio proportional to approximate human tissue concentrations (ERLUX, Mixture 2 (Table 4)). D) 13 component mixture at
fixed ratio proportional to approximate human tissue concentrations (ESCREEN, Mixture 4 (Table 4)). Each graph shows experimental data (dots) with
best fit regression curves (solid black lines) and their 95% confidence belts (dotted black lines). Prediction curves according to concentration addition
are shown as red solid line, with approximate 95% confidence intervals as dotted red lines. The use of extrapolation to extend the range of CA is
shown by a pale red band, which is delimited by worse-case upper and lower assumptions (see text for more details).
doi:10.1371/journal.pone.0043606.g003
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Modulation studies using MODmix showed a clear negative
modulation at a mixture concentration of 1.6 mM (i.e. which
contains 16 modulators each present at 0.1 mM) and 16 mM, but
not at 0.16 mM or lower (Figure 5A).
Effects of single modulators. Screening level data from
studies in which 16 potential modulators were studied individually
is presented in Figure 5B–Q. Data on estrogenicity and toxicity for
these chemicals is listed in Table 7.
Considering the 16 potential modulators studied individually
(Figure 5B–Q): a clear negative modulation was shown by three
chemicals, which were benzo [a] pyrene, cadmium chloride and
PCB126. A possible negative modulation was shown by five
chemicals (lead nitrate, PhIP, DBP, BHA and BHT) whilst no
indication of negative modulation was seen for eight chemicals
(DEHP, mercury chloride, PCB008, PCB153, PCB180, MeIQx,
BBP and DEP). None of the potential modulators showed any
indication of a positive modulation.
We note that the distinction between clear and possible
modulation is somewhat arbitrary due to the low power of these
screening experiments and, for the same reason, strong conclu-
sions of no effect cannot be drawn. Three compounds were
considered to show a clear negative effect: PCB126 began to
suppress the ESCREEN response to the REFmix at concentrations
between 1–10 nM, 50% suppression was reached at 100 nM, and
the suppressive effect appeared to plateau at that level up to
concentrations of 10 mM. When tested alone, PCB126 was
estrogenic in ESCREEN at 10 mM. Cadmium chloride (CdCl2)
began to suppress the REFmix effect at around 10 nM, reached
80% suppression at 10 mM, and the trend in the data suggests that
complete suppression would have been reached if higher
concentrations were tested. Benzo [a] pyrene began to suppress
the effect of REFmix at concentrations between 10 and 100 nM,
and complete suppression was reached by 1 mM.
A quantitative assessment of whether the overall modulation
conformed to CA, based on the modulation observed for the
individual component chemicals, was not made due to the
screening nature of the individual chemical data. However
qualitative comparisons of the concentrations at which negative
modulation was observed (for example, comparing the vertical
dotted line in Figure 5A versus Figure 5B–Q) suggests that the
effects were consistent with additivity as the mixture showed
negative modulation only when the concentration of the
components was in the range at which certain of the individual
components were themselves active (for example BaP, Figure 5B).
Figure 4. Distribution of toxic units. Each graph shows the distribution of toxic units as predicted by CA at the EC10 level for mixtures of
estrogenic compounds tested in the ERLUX and ESCREEN. A) 17 component mixture at fixed mixture ratio proportional to the individual EC10’s
(ERLUX, Mixture1 (Table 4)). B) 16 component mixture at fixed mixture ratio proportional to the individual EC25’s (ESCREEN, Mixture3a (Table 4)). C) 14
component mixture at fixed ratio proportional to approximate human tissue concentrations (ERLUX, Mixture 2 (Table 4)). D) 13 component mixture at
fixed ratio proportional to approximate human tissue concentrations (ESCREEN, Mixture 4 (Table 4)).
doi:10.1371/journal.pone.0043606.g004
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Consequently, dramatic synergies or antagonisms can be qualita-
tively ruled out.
Discussion
The mixture studies reported in this paper show that the CA
model provided good predictions of multicomponent mixture
effects in both the ERLUX and ESCREEN assays. We believe our
mixture study in ERLUX is the largest mixture studied in this
system published to date, and the first to test a non-balanced
design. We compared two types of mixture design, described as
balanced and non-balanced and illustrated by the resulting toxic
unit distributions (Figure 4). Our results showed that, for either
design, CA was a suitable predictor of effects, and thus CA may be
suitable for use in modeling the likely effects of mixtures and
reducing the need to experimentally test every possible mixture.
These observations support previous findings for mixtures. The
question of how relevant the exact non-balanced design is to the
human exposure scenario will require better data on both human
tissue levels and the relationship between in vitro estrogenicity and
gross effects.
We chose to study mixtures in parallel in both the ESCREEN
and ERLUX assays, however in neither assay was there any
evidence of a deviation from the effect predicted by CA. The lack
of a difference between the ERLUX and ESCREEN assays may
be because the assays are not as different as we originally
hypothesised, or because no deviation was observed in either case.
It might have been expected that, if a deviation had occurred, it
would be observed in the more complex ESCREEN and not in the
engineered ERLUX assay. The dose-response curves obtained in
the two assays were very similar and showed almost perfect
correlation (Figure 1).
Studies of potential modulation of the effect (ESCREEN) of
a mixture of estrogenic chemicals revealed negative modulation by
a mixture of 16 modulators, with clearest indications for a role in
this effect for 3 of the modulators (PCB126, CdCl2, BaP). This
fraction (approximately 1 in 5, or 20%) of potential modulators
applies only to this nonrandom sample of chemicals and should
not be directly extrapolated to the wider chemical ‘world’. No
indications for positive modulation were seen for any chemical. A
preliminary analysis suggested that the observed negative modu-
lation was also predictable by the CA model, although the low
power and screening nature of these studies should be considered
before drawing strong conclusions.
Frische et al. have previously examined the modulation of the
estrogenicity of either estradiol or a ternary mixture of estradiol,
estrone and estriol using a genetically engineered yeast estrogen
screen [23]. They observed negative modulation by 2,4-dinitroani-
line (organic solvent) and cycloheximide (antibiotic) and no effect
of mercury chloride of DMSO (organic solvent). Interestingly,
a positive modulation, or synergy, was observed for LAS-12 (a
surfactant) but only at concentrations deemed ‘slightly toxic’ [23].
Our results, for sixteen different potential modulators, are thus
consistent with the general picture observed by Frische et al., in
that typically either negative modulation or no effect was the
observed outcome. We have built on the results of Frische et al. by
using a non-engineered, mammalian assay system in which
interactions might be more readily extrapolated to the in vivo
mammalian situation, by using a much larger reference mixture
(14 rather than 1 or 3 components) and by testing the ‘double’
Table 7. Observations of estrogenicity or toxicity for chemicals screened as potential modulators.
Name of potential modulator Observed modulationa Signs of estrogenicityb Signs of toxicityc
2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP) Possible negative None None
2-Amino-3,8-dimethylimidazo [4,5-f] quinoxaline (MeIQx) None None None
Benzo [a] pyrene (BaP) Clear negative None Possible toxicity at 3 mM and greater
Butyl benzyl phthalate (BBP) None Active at 1 mM or higher Toxic at 100 mM
Butylated hydroxyl anisole (BHA) Possible negative None None
Butylated hydroxytoluene (BHT) Possible negative None None
Cadmium chloride (CdCl2) Clear negative None
Di butyl phthalate (DBP) Possible negative Active at 10 mM or higher None
Di ethyl hexyl phthalate (DEHP) None Active at 1 mM or higher Toxic at 50 mM and greater
Di ethyl phthalate (DEP) None Active at 10 mM or higher None
Lead nitrate (Pb(NO3)2) Possible negative None None
Mercury chloride (HgCl2) None None Possible toxicity at 10 mM and
greater
PCB #126 Clear negative Active at 10 mM or higher None
PCB #153 None None None
PCB #180 None None None
PCB #8 None None None
aresults from modulator screening studies were classified as ‘clear negative’ (reduction in effect of REFmix at multiple concentrations showing an approximately sigmoid
dose-response), ‘possible negative’ (reduction in effect of REFmix at a single concentration or multiple concentrations with a apparent linear concentration-response
relationship) and ‘none’ (no indication of a negative or positive effect).
b‘Active’ indicates a positive signal in ESCREEN (estrogenicity), clearly distinguishable from assay variability and noise and usually supported by a dose-response (i.e. not
reliant on data from only a single concentration).
c‘Possible toxicity’ indicates a decrease in value for treated wells below that of vehicle controls, this signal is small so the assignment of toxicity is not certain; ‘Toxic’
indicates a reduction in signal evoked by increasing concentrations above those at which a chemical showed activity (estrogenicity).
doi:10.1371/journal.pone.0043606.t007
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Figure 5. Results of modulation studies. Each graph shows the effect of a mixture of 16 modulators (A) or one of 16 individual modulators (B–Q),
concentration indicated on the x-axis, on the ESCREEN response evoked by a reference mixture of 14 estrogens (Mixture 3d, Table 4). Experimental
results are shown as grey circles representing each replicate (duplicate testing within the assay) and obtained in three independent (A) or one (B–Q)
experiment (s). Experimental results were normalized by setting the value observed for the REFmix alone, the concentration of which was selected to
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mixture situation in which a mixture of modulators was found to
negatively modulate the effects of a mixture of estrogens.
One possible explanation for the apparent negative modulation
seen in our studies is the occurrence of frank toxicity or so-called
toxic masking [23]. Testing for toxicity in parallel with the
ESCREEN assay is not straightforward and was not routinely
done. Complications include the low initial cell seeding density
and that substantial cell proliferation occurs within the assay if
estrogens are present but does not occur when estrogenic signals
are absent. A standard cell viability assay, the MTT assay, could
not be performed with the initial cell density (signal is too low) and
assay duration of the ESCREEN (possibility of significant cell
growth confounds assessment of cell viability). Performing an
MTT assay with strikingly different parameters to those used in
the ESCREEN was considered likely to remove the relevance of
the cytotoxicity data to the estrogenicity data, and was therefore
not done.
However, although direct cytotoxicity testing was not appro-
priate, a number of observations suggest that the negative
modulation reported here should not be discounted as toxic
masking. 1) Negative modulation was not seen for all chemicals of
a similar type, for example cadmium chloride showed negative
modulation whilst mercury chloride and lead nitrate did not.
Interestingly, the estrogenicity or anti-estrogenicity of cadmium
chloride has been the subject of much attention in the scientific
literature and appears to have a complex nature that cannot be
simply assigned to direct activity at an estrogen receptor [24–26].
2) The concentrations at which negative modulation was seen
were not extremely high and the effects began in the high
nanomolar concentration range. 3) PCB126 showed negative
modulation beginning at concentrations around 10 nM, however
at higher concentrations in the range of 10 mM actual estrogeni-
city was shown (when PCB126 was tested alone) indicating that
toxicity is not likely at the intermediate concentrations where
negative modulation was observed. PCB126 also showed a clear
plateau in its inhibitory effect (negative modulation) whilst frank
toxicity would be expected to result in full inhibition and to not
show a plateau in effect. 4) CdCl2 began to negatively modulate
the estrogenic response at around 10 nM and the effect spanned
several orders of magnitude, whereas frank toxicity might be
expected to show a steeper dose-response relationship. 5) BaP
showed full inhibition at concentrations around 1 mM, however
the residual baseline in the assay was not abolished (which would
be seen as a sub-zero response below zero, Figure 5B), as can occur
when there is frank toxicity. This lack of effect on the baseline
provides an indication for a lack of toxicity, albeit somewhat
crude. Interestingly, BaP was estrogenic when tested alone in the
ERLUX assay (but not when tested alone on in the ESCREEN
assay) possibly indicating that, like cadmium, BaP is capable of an
interaction with the estrogen system that is yet to be fully
understood.
There are some indications in the literature of potential
mechanisms for modulation for all three of the compounds that
showed clear negative modulation, including observed effects on
estrogen signaling that could be subtle or indirect (CdCl2 [24], BaP
[27]) and effects on metabolism such as AhR agonism or
cytochrome P450 enzyme induction (PCB126, BaP [27]; BaP
[28]).
The modulation testing process we adopted provides a scalable
compromise approach to testing compared to an exhaustive
combinatorial approach that would only be feasible in a high-
throughput, automated system, and for which the benefits may not
justify the high costs in time and experimental resources. The use
of parallel low power screening and mixture testing increases the
strength of the observations because they can be used to cross-
validate each other. The definition of modulation, or of modulator
chemicals, is not trivial, since requiring that each potential
modulator has a complete absence of the activity being examined
for modulation requires testing at high concentrations at which
assay function can be impaired and technical issues may confound
interpretation. A clear positive modulation would be less equivocal
than a clear negative modulation, for which toxic masking is an
alternative explanation and must be explicitly considered. Ideally
chemicals would be profiled both for their activity on multiple
receptors or systems, and for modulation of those effects. The
methods used here may be suitable to allow wider consideration of
modulation that has been commonplace to date.
We have shown that negative modulation can be observed in
the ESCREEN and provide indications that the extent of this
modulation should be quantitatively predicted by using informa-
tion from testing of the single components. The possibility of
modulation should be considered when attempting to predict the
effects of mixtures in real human exposure scenarios which are
unlikely to be limited to only chemicals with one defined effect.
The observed negative modulation can be considered to be a large,
convincing deviation from CA/additivity. Our results show that in
vitro models such as the ESCREEN could be useful to explore
significant deviations that may be encountered when the type of
chemicals included in mixture studies is expanded, and that
further studies may be relevant as a precursor to the design of
similar in vivo studies. Finally, the results of our mixture studies
support the growing consensus that conformance to additivity (CA)
should be expected for multicomponent mixture of estrogens, but
consideration of potential modulations is also necessary to
accurately predict the likely outcomes when complex, mixed
exposure scenarios are examined.
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